Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

- Jerusalem, G., Farah, S., Abdi, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O'Reilly, S., Gombos, A., Courtois, A., Ruhstaller, T., Burstein, HJ, Rabaglio, M., Ruepp, B, Ribi, K, Viale, G, Gelber, RD, Coates, AS, Loi, S, Goldhirsch, A, Chirgwin, J., Regan, MM, Colleoni, M, Aebi, S., Karlsson, P., Neven, P., Hitre, E., Graas, M. P., Simoncini, E.

Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer

- de Boer, Richard, Hui, Rina, Lim, Elgene, Yeo, Belinda, Zdenkowski, Nicholas

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

- Saura, Christina, Oliveira, Mafalda, Hlauschek, Dominik, Zardavas, Dimitrios, Jallitsch-Halper, Anita, de la Peña, Lorena, Nuciforo, Paolo, Ballestrero, Alberto, Dubsky, Peter, Lombard, Janine M., Vuylsteke, Peter, Castaneda, Carlos A., Colleoni, Marco, Santos Borges, Giuliarno, Ciruelos, Eva, Fornier, Monica, Boer, Katalin, Bardia, Aditya, Wilson, Timothy R., Stout, Thomas J.

Early participant reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II

- Sestak, I., Smith, S. G., Howell, A., Forbes, J. F., Cuzick, J.

Tailoring adjuvant endocrine therapy for premenopausal breast cancer

- Francis, Prudence A., Pagani, Olivia, Bennefoi, Herve R., Bellet, Meritxell, Martino, Silvana, Geyer, Jr., Charles E., Goetz, Matthew P., Stearns, Vered, Pinotti, Graziella, Puglisi, Fabio, Spazzapan, Simon, Climent, Miguel A., Fleming, Gini F., Pavesi, Lorenzo, Ruhstaller, Thomas, Davidson, Nancy E., Coleman, Robert, Debled, Marc, Buchholz, Stefan, Ingle, James N., Winer, Eric P., Maibach, Rudolf, Rabaglio-Poretti, Manuela, Walley, Barbara A., Ruepp, Barbara, Di Leo, Angelo, Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Regan, Meredith M., Colleoni, Marco, Lang, Istvan, Gomez, Henry L., Tondini, Carlo, Ciruelos, Eva, Burstein, Harold J.

Are SOFT and TEXT results practice changing and how?

- Pagani, Olivia, Regan, Meredith M., Francis, Prudence A.

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

- Huober, J., Cole, B. F., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I.

Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study

- Bliss, Judith M., Kilburn, Lucy S., van de Velde, Cornelius J. H., Lønning, Per. E., Morden, James, Reise, Justine, Cisar, Laura, Menschik, Thomas, Coombes, R. Charles, Coleman, Robert E., Forbes, John F., Coates, Alan S., Jones, Stephen E., Jassem, Jack, Delozier, Thierry, Andersen, Jørn, Paridaens, Robert

Predictive algorithms for adjuvant therapy: transATAC

- Dowsett, Mitch, Salter, Janine, Zabaglo, Lila, Mallon, Elizabeth, Howell, Antony, Buzdar, Aman U., Forbes, John, Pineda, S., Cuzick, Jack